Drug Database
PO

polio vaccine (PoliovacSin)

✓ Approved

Nanolek, LLC · 疫苗 · 疫苗

什么是 polio vaccine?

polio vaccine 是一种疫苗,由Nanolek, LLC研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名PoliovacSin
公司Nanolek, LLC
药物类别疫苗, 大分子
给药途径Unknown
状态Approved

治疗适应症

polio vaccine 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsPoliomyelitis✓ Approved
Surgical and medical proceduresPolio immunisation✓ Approved

相关研究文献

PubMedJournal of public health (Oxford, England)2026-07-27

Cost analysis of vaccine-preventable diseases surveillance in Ethiopia.

Mejia Nelly N, Workineh Aschalew Abayneh AA, Zeleke Eden Dagnachew ED, Beshah Senait Alemayehu SA et al.

This study evaluated the cost of the vaccine-preventable diseases (VPD) surveillance system in Ethiopia to inform budgeting for disease detection, prevention, and control, and planning for transitions from donor funding. This cross-sectional retrospective, bottom-up micro-costing study collected data on resource utilization to conduct VPD surveillance during one fiscal year (2018-2019) in Ethiopia. The study covered 16 VPDs and costs from the government and partners perspective. The estimated economic costs of VPD surveillance in Ethiopia were US$69.11 million or US$0.70 per capita, while financial costs were US$26.83 million or US$0.27 per capita. The largest economic cost was for labor (41.0%) and the largest financial cost was for supplies (36.9%). Resources were mostly allocated to integrated, general disease surveillance (economic: 54.6%; financial: 50.7%), followed by surveillance for measles and rubella (economic: 15.9%; financial: 22.5%) and polio (economic: 12.4%; financial: 15.7%). The main funder was the Ethiopian Ministry of Health (economic: 78.8%; financial 62.6%), including donor resources channeled through the ministry. Human resources were primary drivers of economic costs. Although the Ethiopian VPD surveillance system uses shared resources across multiple VPDs, resulting in scale efficiencies, and the Ethiopian government covers most of its economic costs, a substantial portion relies on direct external donor support.

PMID 42504969
阅读全文 →
PubMedVaccines2026-07-27

Inactivation of Wild Poliovirus with β-Propiolactone.

Kovpak Anastasia A, Pashkov Sergey S, Kostrova Mariia M, Nebesnyi Kirill K et al.

Antiviral vaccines are usually created by inactivating viruses using physical or chemical methods. Inactivation of poliovirus with β-propiolactone (BPL) has advantages, including the absence of a requirement for long-term incubation with the inactivating agent, which minimizes the risk of negative effects of the potentially dangerous substance on the virus and reduces the duration of the inactivation process. BPL was applied at 0.2% (w/v) concentration under two conditions: 4 °C for 24 h and 37 °C for 3 h. Inactivation completeness was confirmed on Vero cell culture, while immunogenicity was assessed in guinea pigs via neutralizing antibody test. Two variants of virus inactivation made it possible to obtain inactivated samples that retained their immunogenic properties. BPL-inactivated samples retained sufficient D-antigen levels and elicited neutralizing antibodies comparable to or exceeding those from formaldehyde-inactivated controls. The inactivation method at 37 °C provided faster inactivation, while at 4 °C it provided a smooth decrease in virus titer. These results confirm that β-propiolactone is a viable alternative to formaldehyde for the production of inactivated polio vaccine (IPV), providing rapid inactivation of the virus compared to inactivation with formaldehyde while maintaining immunogenicity, as confirmed by guinea pig control.

PMID 42506679
阅读全文 →
PubMedVaccines2026-07-27

Untangling the Roots of HPV Vaccine Acceptance in West Virginia: How Hesitancy and Misinformation Shape Parental Decisions.

Guidry Jeanine P D JPD, Laestadius Linnea I LI, Engbersen-Severijns Yil Y, Miller Carrie A CA et al.

West Virginia is of particular concern regarding HPV vaccine hesitancy, currently ranking 45th among U.S. states in HPV vaccine uptake. General vaccine hesitancy and HPV- and HPV vaccine-specific misinformation, both associated with lower vaccination, have increased in recent years, complicating efforts to identify key drivers of HPV vaccine acceptance and effective intervention targets. This study used a Qualtrics survey of n = 330 parents of children aged 0-14 in West Virginia. Measures included parental HPV vaccine acceptance for their youngest child (reflecting either completed vaccination or intention to vaccinate), general vaccine hesitancy measured using the Vaccine Hesitancy Scale (VHS), and endorsement of nine common HPV- and HPV vaccine-specific misinformation statements. Misinformation items were summed and demonstrated good internal reliability (Cronbach's α = 0.868). Hierarchical logistic regression analyses indicated significant racial/ethnic differences across all model steps, with non-White parents less likely to report HPV vaccine acceptance for their child (p < 0.001). In Step 2, lower levels of general vaccine hesitancy predicted higher HPV vaccine acceptance (p < 0.001). In the final model, higher endorsement of HPV- and HPV vaccine-specific misinformation was associated with lower HPV vaccine acceptance (p = 0.035). These findings underscore the independent and additive influence of general vaccine hesitancy and HPV- and HPV vaccine-specific misinformation on parental HPV vaccine acceptance in West Virginia. Community-engaged public health strategies should prioritize strengthening vaccine confidence and directly addressing HPV- and HPV vaccine-specific misinformation, particularly among underserved populations.

PMID 42506645
阅读全文 →
PubMedVaccines2026-07-27

Human Papillomavirus Vaccine Intent and Associated Factors Among the Unvaccinated University Freshmen in the Largest University Town in China.

Yao Hongcen H, Lu Hongmei H, Zhu Qi Q, Shen Jinhua J et al.

Background: Human papillomavirus (HPV) vaccine has been proven a safe, necessary, and effective measure against HPV infection. However, HPV vaccine uptake remains limited among university students in China. This study investigated HPV vaccine intent among university freshmen in the largest university town in China. Methods: A cross-sectional online survey was conducted among unvaccinated female and male freshmen attending seven universities in Songjiang University Town, Shanghai, during 2024-2025. The questionnaire collected sociodemographic characteristics, HPV and HPV-vaccine-related knowledge, awareness, and vaccine intent. Factors associated with HPV vaccine intent were determined. Results: A total of 3397 valid questionnaires were collected, including female (60.02%) and male (39.98%) university freshmen. Overall, 76.12% were aware of HPV, 80.98% were aware of the HPV vaccine, and 84.31% expressed vaccine intent, with significantly higher rates among females than males (each p < 0.001). Socioeconomics, knowledge, awareness, sexual behavior, and HPV testing history were significantly associated with vaccine intent (each p < 0.05). The most common reason for no intent was perceived low risk of HPV-related diseases (40.53%). The most expected improvement measures were regulatory confirmation of vaccine safety and effectiveness (37.71%) and healthcare professionals' recommendations (37.71%), with no gender difference (each p > 0.05). Notably, 4.00% refused HPV vaccination, regardless of improvement measures. Additionally, most respondents preferred financial supporting policies, regardless of gender or vaccine intent (each p > 0.05). Conclusions: University freshmen showed the disparity between high awareness/intent and low knowledge. Financial considerations may influence HPV vaccination decisions. Thus, improving knowledge, particularly among males, and providing financial support may enhance HPV vaccine intent.

PMID 42506658
阅读全文 →
PubMedZhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]2026-07-27

[Research progress in combination vaccines containing sabin strain inactivated poliovirus vaccine].

Fu Y X YX, Cai L K LK, Liang J L JL, Zhao T T et al.

Sabin strain inactivated poliovirus vaccine (sIPV), derived from attenuated Sabin poliovirus strains, has emerged as a promising alternative to both oral poliovirus vaccine (OPV) and conventional inactivated poliovirus vaccine (cIPV). It eliminates the risk of vaccine-associated paralytic poliomyelitis (VAPP) and the emergence of vaccine-derived polioviruses (VDPVs). In addition, sIPV demonstrates superior biosafety and vaccine safety during production and administration compared with cIPV. The integration of sIPV into combination vaccines with other routine immunization antigens can reduce the number of injections and streamline immunization schedules, making sIPV-containing combination vaccines a key focus of recent research. Japan launched the world's first sIPV-containing tetravalent vaccine in 2012, followed by the introduction of an sIPV-containing pentavalent vaccine in 2024. In China, a standalone sIPV was licensed in 2015, and multiple sIPV-containing combination vaccines are currently in clinical trials or preclinical development. The primary challenges for these vaccines include antigen compatibility within combination formulations and the scalability of sIPV production. Future strategies, such as the use of innovative adjuvants and intradermal administration, may enable antigen-sparing approaches. This review provides a comprehensive summary of the development and application of sIPV-containing combination vaccines, aiming to inform and guide ongoing vaccine research and development in China.

PMID 42503940
阅读全文 →
PubMedVaccines2026-07-27

Parental Vaccine Hesitancy in the Post-COVID-19 Era: Results from a Cross-Sectional Survey in the United States, 2025.

Duza Syeda Sharmin SS, Blackburn Christine Crudo CC, Rico Mayra M, Boyce Matthew R MR

Background/Objectives: Vaccine hesitancy has long been recognized to pose a significant barrier to achieving optimal immunization coverage and as a leading public health threat. However, much of the existing research on parental hesitancy toward routine childhood vaccines was conducted prior to the COVID-19 pandemic. Acknowledging the impact that this public health emergency had on attitudes toward vaccination, there is a need to conduct additional research into contemporary predictors of parental vaccine hesitancy. Methods: We conducted a survey in August 2025 to characterize vaccine hesitancy attitudes in parents in the United States. A series of 10 statements about vaccines was presented to study participants, who were asked to indicate their agreement with the statements using 5-point Likert scales. A vaccine hesitancy index measure was then calculated by averaging the scores, where higher scores corresponded to higher levels of vaccine hesitancy. A hierarchical regression analysis was then conducted to identify participant characteristics that were associated with vaccine hesitancy. Results: A total of 1016 individuals were included in the analysis. Simple linear regression suggested that education, annual household income, and politics were associated with vaccine hesitancy. The fully adjusted multiple linear regression model that accounted for participant demographic, socioeconomic, geographic, and political characteristics suggested significant associations between race, education, and partisanship. Conclusions: Significant associations exist between parental vaccine hesitancy and race, education, and partisanship. These results contribute to our understanding of vaccine hesitancy in a post-COVID-19 world and suggest that social, educational, and political factors meaningfully influence parental vaccine hesitancy in the United States.

PMID 42506638
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多polio vaccine